Câncer de pulmão: novo tratamento reduz em 27% risco de morte

[{"selector":"#anim-b432a54a-5080-45a7-94c2-65bc655903e2","keyframes":{"opacity":[0,1]},"delay":0,"duration":1000,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-230d6c3c-abc9-4dd7-aea4-87b1f91f443c","keyframes":{"opacity":[0,1]},"delay":0,"duration":500,"easing":"cubic-bezier(.3,0,.55,1)","fill":"both"}] [{"selector":"#anim-6004833b-7a91-424f-a436-9139a5a1ccea","keyframes":{"transform":["scale(0.3333333333333333)","scale(1)"]},"delay":0,"duration":500,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] [{"selector":"#anim-91603ee0-f9f0-47ac-b281-d892a51cf367","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Unsplash

[{"selector":"#anim-f44d6e00-dbe7-4901-8f06-b25cb74ef543","keyframes":{"opacity":[0,1]},"delay":0,"duration":1500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-ec0e83fc-4f8f-44ab-bedb-7329ebcee11f","keyframes":{"opacity":[0,1]},"delay":0,"duration":500,"easing":"cubic-bezier(.3,0,.55,1)","fill":"both"}] [{"selector":"#anim-3df3048a-4652-49e5-bd0d-2544b2bd6875","keyframes":{"transform":["scale(0.3333333333333333)","scale(1)"]},"delay":0,"duration":500,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] [{"selector":"#anim-dcb0bf9b-2a72-4e66-8988-4399256aaf46","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] A Anvisa aprovou uma nova indicação para o durvalumabe, uma imunoterapia agora autorizada para tratar câncer de pulmão de pequenas células em estágio limitado, reduzindo em até 27% o risco de morte após quimio e radioterapia Unsplash

[{"selector":"#anim-adb2f518-5739-4614-b029-00bd3b4f2f84","keyframes":{"opacity":[0,1]},"delay":0,"duration":1500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-6a687783-ce32-48c7-a4a3-83a8ebe0cf52","keyframes":{"opacity":[0,1]},"delay":0,"duration":500,"easing":"cubic-bezier(.3,0,.55,1)","fill":"both"}] [{"selector":"#anim-130ee764-bacb-410b-a944-40eb38af09cf","keyframes":{"transform":["scale(0.3333333333333333)","scale(1)"]},"delay":0,"duration":500,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] [{"selector":"#anim-387137ce-28bb-475b-a1a4-26cae81cfc4a","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Este tipo de câncer é o mais agressivo da doença, com rápida evolução e baixas taxas de sobrevida, afetando principalmente fumantes de longa data e pacientes idosos Unsplash

[{"selector":"#anim-43f82580-19aa-4a7c-9fc7-4e9861e97f8c","keyframes":{"opacity":[0,1]},"delay":0,"duration":1500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-1432e8da-934c-4e0b-ab13-1e0a497e78d5","keyframes":{"opacity":[0,1]},"delay":0,"duration":500,"easing":"cubic-bezier(.3,0,.55,1)","fill":"both"}] [{"selector":"#anim-8a0ad698-6447-4e70-976b-814eb38b0144","keyframes":{"transform":["scale(0.3333333333333333)","scale(1)"]},"delay":0,"duration":500,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] [{"selector":"#anim-7f8fb9ab-a89b-4240-a021-f3e06c27f266","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] A aprovação foi baseada no estudo ADRIATIC, que demonstrou que 57% dos pacientes tratados com durvalumabe estavam vivos após três anos de acompanhamento Unsplash

[{"selector":"#anim-68c19c54-d29b-4565-8380-a23f0a2de3e0","keyframes":{"opacity":[0,1]},"delay":0,"duration":1500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-1f53beec-c70d-4732-b116-2860081b5a08","keyframes":{"opacity":[0,1]},"delay":0,"duration":500,"easing":"cubic-bezier(.3,0,.55,1)","fill":"both"}] [{"selector":"#anim-dc86aecb-508d-41b8-9b45-8d3c763b4b10","keyframes":{"transform":["scale(0.3333333333333333)","scale(1)"]},"delay":0,"duration":500,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] [{"selector":"#anim-a54c8378-6611-4d56-8dc4-0c0ae2ff676c","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] A imunoterapia funciona ao desbloquear mecanismos que permitem ao sistema imunológico identificar e combater o câncer, aumentando as chances de sobrevida Unsplash

[{"selector":"#anim-4526fe02-4900-43f3-a702-38290f0c50e3","keyframes":{"opacity":[0,1]},"delay":0,"duration":1500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-ac2f17f7-d392-4bd4-a772-b9993844570f","keyframes":{"opacity":[0,1]},"delay":0,"duration":500,"easing":"cubic-bezier(.3,0,.55,1)","fill":"both"}] [{"selector":"#anim-430252ee-7305-46a0-bf91-79a4c4254f64","keyframes":{"transform":["scale(0.3333333333333333)","scale(1)"]},"delay":0,"duration":500,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] [{"selector":"#anim-3bd7b778-58a5-4850-a99b-abceb247366e","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Por 20 anos, não houve avanços significativos no tratamento desse tipo de câncer, e o durvalumabe marca uma nova era ao oferecer ganhos relevantes de sobrevida Unsplash

[{"selector":"#anim-e140d5d4-0de5-4782-b1d4-1d43a7ab54d0","keyframes":{"opacity":[0,1]},"delay":0,"duration":1500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-094a353f-b008-4670-ae9f-dece0d72410b","keyframes":{"opacity":[0,1]},"delay":0,"duration":500,"easing":"cubic-bezier(.3,0,.55,1)","fill":"both"}] [{"selector":"#anim-d7dafff7-91a0-4b05-84dd-320ea3e0fba6","keyframes":{"transform":["scale(0.3333333333333333)","scale(1)"]},"delay":0,"duration":500,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] [{"selector":"#anim-ff280837-49b2-45c0-ba14-5f2cdfe81d53","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] O medicamento se consolida como novo padrão de tratamento, transformando o cenário desafiador dessa doença com eficácia comprovada e potencial para salvar vidas Unsplash

CNNBRASIL.COM.BR

[{"selector":"#anim-38e3b434-c0e1-4b37-9029-d729a2998854","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-f145ffd4-11c0-4ff9-899c-48380c5b1fda","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-942f66db-d2b8-47d7-879e-ff43557f8bbe","keyframes":{"opacity":[0,1]},"delay":0,"duration":1000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-114dcf86-3af9-4423-a901-f69d468b6084","keyframes":{"transform":["translate3d(0px, 2132.63615%, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":1000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-d83b48f8-ebdf-4ab9-8f24-b29f8bae150a","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-89c6368b-0392-4376-b6a8-751c63f51723","keyframes":{"transform":["translate3d(-117.84387%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-1ef36217-8deb-437d-a28b-e2f1a3f9a2ca","keyframes":{"opacity":[0,1]},"delay":0,"duration":1000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-a9505cb2-cc75-4773-84ae-1e2fb8b217b1","keyframes":{"transform":["translate3d(0px, 1223.93157%, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":1000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] Unsplash leia mais em